Webster K. Cavenee

Ludwig Institute for Cancer Research

Affiliated withLudwig Institute for Cancer Research University of California, San Diego

Research Area

Biography

Webster K. Cavenee has not added Biography.
If you are Webster K. Cavenee and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 5	2018

Other Publications

Article	Year
Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 9342366	1997
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 9356475	1997
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 9576951	1998
In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 9689095	1998
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 10377430	1999
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 10890917	2000
Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 11171995	2001
Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy\| PubMed ID: 11504467	1999
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. International journal of cancer. Journal international du cancer\| PubMed ID: 11920591	2002
Genetics and new approaches to cancer therapy. Carcinogenesis\| PubMed ID: 12016138	2002
A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. Journal of neurochemistry\| PubMed ID: 12065666	2002
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer research\| PubMed ID: 12438278	2002
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 12515857	2003
Preparing for serendipity. Cancer biology & therapy\| PubMed ID: 12750567	2003
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 12808131	2003
The recessive nature of dominance. Genes, chromosomes & cancer\| PubMed ID: 14566850	2003
Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 14978268	2004
Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Molecular and cellular biology\| PubMed ID: 15456872	2004
Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 15659546	2005
PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell cycle (Georgetown, Tex.)\| PubMed ID: 15753657	2005
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16144944	2005
PCAF modulates PTEN activity. The Journal of biological chemistry\| PubMed ID: 16829519	2006
The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17363548	2007
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & development\| PubMed ID: 17974913	2007
PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17986608	2007
Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome research\| PubMed ID: 18042645	2008
Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell cycle (Georgetown, Tex.)\| PubMed ID: 18414034	2008
Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 20133782	2010
Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell cycle (Georgetown, Tex.)\| PubMed ID: 20404502	2010
Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PloS one\| PubMed ID: 20532243	2010
KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. Journal of the National Cancer Institute\| PubMed ID: 20660366	2010
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese journal of cancer\| PubMed ID: 21192840	2011
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of cell science\| PubMed ID: 21878501	2011
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 22891331	2012
Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer. Cancer prevention research (Philadelphia, Pa.)\| PubMed ID: 22911109	2012
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis\| PubMed ID: 23455378	2013
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer discovery\| PubMed ID: 23533263	2013
EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. Cell metabolism\| PubMed ID: 23707073	2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24030701	2013
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell metabolism\| PubMed ID: 24140020	2013
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.)\| PubMed ID: 24310612	2014
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer biology & medicine\| PubMed ID: 24349829	2013
Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer research\| PubMed ID: 24436148	2014
mTORC2 dictates Warburg effect and drug resistance. Cell cycle (Georgetown, Tex.)\| PubMed ID: 24583874	2014
mTORC2 in the center of cancer metabolic reprogramming. Trends in endocrinology and metabolism: TEM\| PubMed ID: 24856037	2014
Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncology letters\| PubMed ID: 24944646	2014
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer research\| PubMed ID: 25432173	2015
Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 25583476	2015
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature reviews. Cancer\| PubMed ID: 25855404	2015
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget\| PubMed ID: 26059434	2015
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 26080435	2015
Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 26170313	2015
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular cell\| PubMed ID: 26455392	2015
mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain pathology (Zurich, Switzerland)\| PubMed ID: 26526943	2015
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer cell\| PubMed ID: 27070703	2016
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica\| PubMed ID: 27157931	2016
Cancer metabolism as a central driving force of glioma pathogenesis. Brain tumor pathology\| PubMed ID: 27295313	2016
mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. BioEssays : news and reviews in molecular, cellular and developmental biology\| PubMed ID: 27427440	2016
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer cell\| PubMed ID: 27746144	2016
Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of controlled release : official journal of the Controlled Release Society\| PubMed ID: 27825958	2016
Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 28011764	2017
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature\| PubMed ID: 28178237	2017
PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature communications\| PubMed ID: 28497778	2017
Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 28607091	2017
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & development\| PubMed ID: 28724615	2017
Going viral? Linking the etiology of human prostate cancer to the long noncoding RNA and oncogenic viruses. EMBO molecular medicine\| PubMed ID: 28751581	2017
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 28814435	2018
Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nature communications\| PubMed ID: 29203859	2017